Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection. OBSERVATIONS: No proven effective therapies for this virus currently exist. The rapidly expanding knowledge regarding SARS-CoV-2 virology provides a significant number of potential drug targets. The most promising therapy is remdesivir. Remdesivir has potent in vitro activity against SARS-CoV-2, but it is not US Food and Drug Administration approved and currently is being tested in ongoing randomized trials. Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended. Current clinical evidence does not support stopping angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with COVID-19. CONCLUSIONS AND RELEVANCE: The COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918. The speed and volume of clinical trials launched to investigate potential therapies for COVID-19 highlight both the need and capability to produce high-quality evidence even in the middle of a pandemic. No therapies have been shown effective to date.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
RetractedClinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Cited by
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020) · JAMA · doi:10.1001/jama.2020.12839 · Cited by 4,609
Multisystem Inflammatory Syndrome in U.S. Children and Adolescents
Feldstein, L. R., Rose, E. B., Horwitz, S. M., Collins, J. P., Newhams, M. M., Son, M. B. F., Newburger, J. W., Kleinman, L. C., Heidemann, S. M., Martin, A. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021680 · Cited by 2,643
Huang, Y., Yang, C., Xu, X.-F., Xu, W., & Liu, S.-W. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0485-4 · Cited by 2,224
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Grasselli, G., Greco, M., Zanella, A., Albano, G., Antonelli, M., Bellani, G., Bonanomi, E., Cabrini, L., Carlesso, E., Castelli, G., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.3539 · Cited by 1,612
COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives
Nishiga, M., Wang, D. W., Han, Y., Lewis, D. B., & Wu, J. C. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0413-9 · Cited by 1,409
Myocarditis and inflammatory cardiomyopathy: current evidence and future directions
Tschöpe, C., Ammirati, E., Bozkurt, B., Caforio, A. L. P., Cooper, L. T., Felix, S. B., Hare, J. M., Heidecker, B., Heymans, S., Hübner, N., et al. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00435-x · Cited by 1,217
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Covid-19 and Kidney Transplantation
Akalin, E., Azzi, Y., Bartash, R., Seethamraju, H., Parides, M., Hemmige, V., Ross, M., Forest, S., Goldstein, Y. D., Ajaimy, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2011117 · Cited by 749
Immune response, inflammation, and the clinical spectrum of COVID-19
García, L. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01441 · Cited by 739
Lax, S. F., Skok, K., Zechner, P., Kessler, H. H., Kaufmann, N., Koelblinger, C., Vander, K., Bargfrieder, U., & Trauner, M. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2566 · Cited by 730
Nadim, M. K., Forni, L. G., Mehta, R. L., Connor, M. J., Liu, K. D., Ostermann, M., Rimmelé, T., Zarbock, A., Bell, S., Bihorac, A., et al. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00356-5 · Cited by 690
How COVID-19 induces cytokine storm with high mortality
Hojyo, S., Uchida, M., Tanaka, K., Hasebe, R., Tanaka, Y., Murakami, M., & Hirano, T. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-020-00146-3 · Cited by 663
“Another anti-IL-6R antibody, SAR, used for rheumatoid arthritis [74], has been tested in a multicenter, double-blind, clinical phase II/III study in patients with severe COVID-19 (NCT04315298) [75].”
MethodOutcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19
Magagnoli, J., Narendran, S., Pereira, F., Cummings, T. H., Hardin, J. W., Sutton, S. S., & Ambati, J. (2020) · Med · doi:10.1016/j.medj.2020.06.001 · Cited by 656
Artificial intelligence in COVID-19 drug repurposing
Zhou, Y., Wang, F., Tang, J., Nussinov, R., & Cheng, F. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30192-8 · Cited by 636
The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections
Machhi, J., Herskovitz, J., Senan, A. M., Dutta, D., Nath, B., Oleynikov, M. D., Blomberg, W. R., Meigs, D. D., Hasan, M., Patel, M., et al. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-020-09944-5 · Cited by 617
Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic
Weiss, C., Carriere, M., Fusco, L., Capua, I., Regla-Nava, J. A., Pasquali, M., Scott, J. A., Vitale, F., Unal, M. A., Mattevi, C., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c03697 · Cited by 601
Bäuerle, A., Teufel, M., Musche, V., Weismüller, B., Kohler, H., Hetkamp, M., Dörrie, N., Schweda, A., & Skoda, E.-M. (2020) · Journal of Public Health · doi:10.1093/pubmed/fdaa106 · Cited by 597
Depression, anxiety and stress among indians in times of Covid-19 lockdown.
Rehman, U., Shahnawaz, M. G., Khan, N. H., Kharshiing, K. D., Khursheed, M., Gupta, K., Kashyap, D., & Uniyal, R. (2021) · Community Mental Health Journal · doi:10.1007/s10597-020-00664-x · Cited by 579
“Covid-19, commonly known as the novel Coronavirus is believed to have originated from a wet market in Wuhan, China, and has spread all over the world, resulting in a large number of hospitalizations and deaths (Wang et al.”
BackgroundInfluentialThe SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA
Cubuk, J., Alston, J. J., Incicco, J. J., Singh, S., Stuchell-Brereton, M. D., Ward, M. D., Zimmerman, M. I., Vithani, N., Griffith, D., Wagoner, J. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21953-3 · Cited by 576
Arshad, S., Kilgore, P., Chaudhry, Z. S., Jacobsen, G., Wang, D. D., Huitsing, K., Brar, I., Alangaden, G. J., Ramesh, M. S., McKinnon, J. E., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.06.099 · Cited by 546
Zhao, M.-M., Yang, W.-L., Yang, F.-Y., Zhang, L., Huang, W.-J., Hou, W., Fan, C.-F., Jin, R.-H., Feng, Y.-M., Wang, Y.-C., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00558-8 · Cited by 515
Pruijssers, A. J., George, A. S., Schäfer, A., Leist, S. R., Gralinksi, L. E., Dinnon, K. H., Yount, B. L., Agostini, M. L., Stevens, L. J., Chappell, J. D., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107940 · Cited by 510
Dequin, P.-F., Heming, N., Meziani, F., Plantefève, G., Voiriot, G., Badié, J., François, B., Aubron, C., Ricard, J.-D., Ehrmann, S., et al. (2020) · JAMA · doi:10.1001/jama.2020.16761 · Cited by 499
Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19
Somers, E. C., Eschenauer, G. A., Troost, J. P., Golob, J. L., Gandhi, T. N., Wang, L., Zhou, N., Petty, L. A., Baang, J. H., Dillman, N. O., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa954 · Cited by 497
A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies
Hassan, A. O., Case, J. B., Winkler, E. S., Thackray, L. B., Kafai, N. M., Bailey, A. L., McCune, B. T., Fox, J. M., Chen, R. E., Alsoussi, W. B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.011 · Cited by 494
Musculoskeletal Consequences of COVID-19
Disser, N. P., De Micheli, A. J., Schonk, M. M., Konnaris, M. A., Piacentini, A. N., Edon, D. L., Toresdahl, B. G., Rodeo, S. A., Casey, E. K., & Mendias, C. L. (2020) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.20.00847 · Cited by 465
COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons
Nile, S. H., Nile, A., Qiu, J., Li, L., Jia, X., & Kai, G. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.05.002 · Cited by 440
New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis
Hou, Y., Zhao, J., Martin, W., Kallianpur, A., Chung, M. K., Jehi, L., Sharifi, N., Erzurum, S., Eng, C., & Cheng, F. (2020) · BMC Medicine · doi:10.1186/s12916-020-01673-z · Cited by 438
Jeronimo, C. M. P., Farias, M. E. L., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Safe, I. P., Borba, M. G. S., Netto, R. L. A., Maciel, A. B. S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1177 · Cited by 434
COVID-19 and the elderly: insights into pathogenesis and clinical decision-making
Perrotta, F., Corbi, G., Mazzeo, G., Boccia, M., Aronne, L., D’Agnano, V., Komici, K., Mazzarella, G., Parrella, R., & Bianco, A. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01631-y · Cited by 420
Self, W. H., Semler, M. W., Leither, L. M., Casey, J. D., Angus, D. C., Brower, R. G., Chang, S. Y., Collins, S. P., Eppensteiner, J. C., Filbin, M. R., et al. (2020) · JAMA · doi:10.1001/jama.2020.22240 · Cited by 417
Mohammed, I., Nauman, A., Paul, P., Ganesan, S., Chen, K.-H., Jalil, S. M. S., Jaouni, S. H., Kawas, H., Khan, W. A., Vattoth, A. L., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2027160 · Cited by 406
Stigma and Discrimination During COVID-19 Pandemic
Bhanot, D., Singh, T., Verma, S. K., & Sharad, S. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2020.577018 · Cited by 393
COVID-19 vaccines: The status and perspectives in delivery points of view
Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375
“These treatments are targeted to achieve lowered SARS-CoV-2 burden in patients, alleviate severe symptoms, and slow the progress of COVID-19 [132].”
Lim, Z. J., Subramaniam, A., Ponnapa Reddy, M., Blecher, G., Kadam, U., Afroz, A., Billah, B., Ashwin, S., Kubicki, M., Bilotta, F., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202006-2405oc · Cited by 369
Serial interval and incubation period of COVID-19: a systematic review and meta-analysis
Alene, M., Yismaw, L., Assemie, M. A., Ketema, D. B., Gietaneh, W., & Birhan, T. Y. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-05950-x · Cited by 354
Wu, Y., Kang, L., Guo, Z., Liu, J., Liu, M., & Liang, W. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.28008 · Cited by 350
Muralidar, S., Ambi, S. V., Sekaran, S., & Krishnan, U. M. (2020) · Biochimie · doi:10.1016/j.biochi.2020.09.018 · Cited by 346
Ma, X., Zou, F., Yu, F., Li, R., Yuan, Y., Zhang, Y., Zhang, X., Deng, J., Chen, T., Song, Z., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.11.015 · Cited by 342
del Amo, J., Polo, R., Moreno, S., Díaz, A., Martínez, E., Arribas, J. R., Jarrín, I., & Hernán, M. A. (2020) · Annals of Internal Medicine · doi:10.7326/m20-3689 · Cited by 324
Rastogi, A., Bhansali, A., Khare, N., Suri, V., Yaddanapudi, N., Sachdeva, N., Puri, G. D., & Malhotra, P. (2022) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-139065 · Cited by 317
COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies
Salian, V. S., Wright, J. A., Vedell, P. T., Nair, S., Li, C., Kandimalla, M., Tang, X., Carmona Porquera, E. M., Kalari, K. R., & Kandimalla, K. K. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00608 · Cited by 315
COVID ‐19 in Nursing Homes: Calming the Perfect Storm
Ouslander, J. G., & Grabowski, D. C. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16784 · Cited by 313
Kreer, C., Zehner, M., Weber, T., Ercanoglu, M. S., Gieselmann, L., Rohde, C., Halwe, S., Korenkov, M., Schommers, P., Vanshylla, K., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.044 · Cited by 309
A materials-science perspective on tackling COVID-19
Tang, Z., Kong, N., Zhang, X., Liu, Y., Hu, P., Mou, S., Liljeström, P., Shi, J., Tan, W., Kim, J. S., et al. (2020) · Nature Reviews Materials · doi:10.1038/s41578-020-00247-y · Cited by 303
Special Article - Acute myocardial injury in patients hospitalized with COVID-19 infection: A review
Bavishi, C., Bonow, R. O., Trivedi, V., Abbott, J. D., Messerli, F. H., & Bhatt, D. L. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.05.013 · Cited by 298
Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy
Ciceri, F., Castagna, A., Rovere-Querini, P., De Cobelli, F., Ruggeri, A., Galli, L., Conte, C., De Lorenzo, R., Poli, A., Ambrosio, A., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108509 · Cited by 293
Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective
Panyod, S., Ho, C.-T., & Sheen, L.-Y. (2020) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2020.05.004 · Cited by 290
Wang, N., Zhan, Y., Zhu, L., Hou, Z., Liu, F., Song, P., Qiu, F., Wang, X., Zou, X., Wan, D., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.07.005 · Cited by 287
Al-Karmalawy, A. A., Dahab, M. A., Metwaly, A. M., Elhady, S. S., Elkaeed, E. B., Eissa, I. H., & Darwish, K. M. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.661230 · Cited by 286
Zhang, J. J. Y., Lee, K. S., Ang, L. W., Leo, Y. S., & Young, B. E. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa576 · Cited by 285
Udwadia, Z. F., Singh, P., Barkate, H., Patil, S., Rangwala, S., Pendse, A., Kadam, J., Wu, W., Caracta, C. F., & Tandon, M. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.11.142 · Cited by 282
Emergency surgery during the COVID-19 pandemic: what you need to know for practice
De Simone, B., Chouillard, E., Di Saverio, S., Pagani, L., Sartelli, M., Biffl, W., Coccolini, F., Pieri, A., Khan, M., Borzellino, G., et al. (2020) · The Annals of The Royal College of Surgeons of England · doi:10.1308/rcsann.2020.0097 · Cited by 269
Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease
Berretta, A. A., Silveira, M. A. D., Cóndor Capcha, J. M., & De Jong, D. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110622 · Cited by 269
Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients
Klopfenstein, T., Zayet, S., Lohse, A., Balblanc, J.-C., Badie, J., Royer, P.-Y., Toko, L., Mezher, C., Kadiane-Oussou, N. J., Bossert, M., et al. (2020) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2020.05.001 · Cited by 266
Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS‐CoV‐2
Mendoza, E. J., Manguiat, K., Wood, H., & Drebot, M. (2020) · Current Protocols in Microbiology · doi:10.1002/cpmc.105 · Cited by 261
Rao, L., Xia, S., Xu, W., Tian, R., Yu, G., Gu, C., Pan, P., Meng, Q.-F., Cai, X., Qu, D., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014352117 · Cited by 260
Madhavan, M. V., Bikdeli, B., Gupta, A., Jimenez, D., Burton, J. R., Der Nigoghossian, C., Chuich, T., Nouri, S. N., Dreyfus, I., Driggin, E., et al. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1713152 · Cited by 258
Cheng, Y.-W., Chao, T.-L., Li, C.-L., Chiu, M.-F., Kao, H.-C., Wang, S.-H., Pang, Y.-H., Lin, C.-H., Tsai, Y.-M., Lee, W.-H., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108254 · Cited by 257
Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning
Zeng, X., Song, X., Ma, T., Pan, X., Zhou, Y., Hou, Y., Zhang, Z., Li, K., Karypis, G., & Cheng, F. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00316 · Cited by 257
HIF-1α promotes SARS-CoV-2 infection and aggravates inflammatory responses to COVID-19
Tian, M., Liu, W., Li, X., Zhao, P., Shereen, M. A., Zhu, C., Huang, S., Liu, S., Yu, X., Yue, M., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00726-w · Cited by 253
Biological age is increased by stress and restored upon recovery
Poganik, J. R., Zhang, B., Baht, G. S., Tyshkovskiy, A., Deik, A., Kerepesi, C., Yim, S. H., Lu, A. T., Haghani, A., Gong, T., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.03.015 · Cited by 246
Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape
Ku, Z., Xie, X., Davidson, E., Ye, X., Su, H., Menachery, V. D., Li, Y., Yuan, Z., Zhang, X., Muruato, A. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20789-7 · Cited by 160
Emerging Technologies for Use in the Study, Diagnosis, and Treatment of Patients with COVID-19
Tsikala Vafea, M., Atalla, E., Georgakas, J., Shehadeh, F., Mylona, E. K., Kalligeros, M., & Mylonakis, E. (2020) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-020-00629-w · Cited by 153
Current Status of COVID-19 Therapies and Drug Repositioning Applications
Altay, O., Mohammadi, E., Lam, S., Turkez, H., Boren, J., Nielsen, J., Uhlen, M., & Mardinoglu, A. (2020) · iScience · doi:10.1016/j.isci.2020.101303 · Cited by 98
“As examples of the most common treatment options, chloroquine and hydroxychloroquine, both antimalarial agents with anti-inflammatory and immunomodulatory activities, have shown inhibitory activity for SARS-CoV-2 similar to previous studies on SARS-CoV-1 and MERS-CoV (Sanders et al., 2020).”
InfluentialSuperio, D. L., Anderson, K. L., Oducado, R. M. F., Luceño, M. T., Palcullo, V. E. V., & Bendalian, M. V. T. (2021) · International Journal of Disaster Risk Reduction · doi:10.1016/j.ijdrr.2021.102414 · Cited by 73
Prats-Uribe, A., Sena, A. G., Lai, L. Y. H., Ahmed, W.-U.-R., Alghoul, H., Alser, O., Alshammari, T. M., Areia, C., Carter, W., Casajust, P., et al. (2021) · BMJ · doi:10.1136/bmj.n1038 · Cited by 68
Wielgus, B., Urban, W., Patriak, A., & Cichocki, Ł. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17238764 · Cited by 51
“However, at this stage, symptomatic treatment is the main therapeutic choice [4,5].”
BackgroundFighting COVID-19 with Artificial Intelligence
Monteleone, S., Kellici, T. F., Southey, M., Bodkin, M. J., & Heifetz, A. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1787-8_3 · Cited by 17
Wang, Z., Guo, K., Gao, P., Pu, Q., Wu, M., Li, C., & Hur, J. (2020) · arXiv · doi:10.48550/arxiv.2005.07856 · Cited by 9
Lombrea, A., Romanescu, M., Jianu, N., Andor, M., Suciu, M., Man, D. E., Danciu, C., Dehelean, C. A., & Buda, V. (2023) · Pharmaceuticals · doi:10.3390/ph16060853 · Cited by 8
“The pathogenesis of COVID-19 involves immune dysfunction and cytokine storm, as evidenced by various studies [45,46].”
BackgroundEarly outcome detection for COVID-19 patients
Sîrbu, A., Barbieri, G., Faita, F., Ferragina, P., Gargani, L., Ghiadoni, L., & Priami, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-97990-1 · Cited by 5
Metadata
- Authors
- Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2020-04-13
- Volume
- 323
- Issue
- 18
- Pages
- 1824-1836
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3016084006
- Cited by
- 2,347
- References
- 77
- FWCI
- 67.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.